{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:49:22Z","timestamp":1776854962344,"version":"3.51.2"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11102-023-01342-3","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T17:02:10Z","timestamp":1689872530000},"page":"495-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Risk of impulse control disorders in patients with Cushing\u2019s disease: do not blame cabergoline but do not give up caution"],"prefix":"10.1007","volume":"26","author":[{"given":"Cem","family":"Sulu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurdan","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seher","family":"Tanrikulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema","family":"Ciftci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feyza","family":"Yener Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betul","family":"Sarac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif Burcu","family":"Ersungur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezgi","family":"Tanriover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hande Mefkure","family":"Ozkaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burc Cagri","family":"Poyraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8329-140X","authenticated-orcid":false,"given":"Pinar","family":"Kadioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"1342_CR1","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"B Biller","year":"2008","unstructured":"Biller B, Grossman AB, Stewart P et al (2008) Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454\u20132462","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1210\/edrv-14-4-443","volume":"14","author":"JW Miller","year":"1993","unstructured":"Miller JW, Crapo L (1993) The medical treatment of Cushing\u2019s syndrome. Endocr Rev 14:443\u2013458","journal-title":"Endocr Rev"},{"key":"1342_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1530\/EJE-12-0921","volume":"168","author":"KI Alexandraki","year":"2013","unstructured":"Alexandraki KI, Kaltsas GA, Isidori AM et al (2013) Long-term remission and recurrence rates in Cushing\u2019s disease: predictive factors in a single-centre study. Eur J Endocrinol 168:639\u2013648","journal-title":"Eur J Endocrinol"},{"key":"1342_CR4","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BM, Findling JW et al (2015) Treatment of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 100:2807\u20132831","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101514","volume":"35","author":"ML Gheorghiu","year":"2021","unstructured":"Gheorghiu ML (2021) Updates in the outcomes of radiation therapy for Cushing\u2019s disease. Best Pract Res Clin Endocrinol Metab 35:101514","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1342_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/17446651.2020.1802243","volume":"15","author":"C Capatina","year":"2020","unstructured":"Capatina C, Hinojosa-Amaya JM, Poiana C et al (2020) Management of patients with persistent or recurrent Cushing\u2019s disease after initial pituitary surgery. Expert Rev Endocrinol Metab 15:321\u2013339","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1342_CR7","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-09-671"},{"key":"1342_CR8","unstructured":"https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=288709"},{"key":"1342_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.rvsc.2007.08.009","volume":"85","author":"V Castillo","year":"2007","unstructured":"Castillo V, G\u00f3mez N, Lalia J et al (2007) Cushing\u2019s disease in dogs: cabergoline treatment. Res Vet Sci 85:26\u201334","journal-title":"Res Vet Sci"},{"key":"1342_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R, De Martino MC, Cappabianca P et al (2009) The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94:223\u2013230","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR11","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1210\/jc.2003-030837","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Ferone D, De Herder W et al (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452\u20132462","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","volume":"17","author":"M Barbot","year":"2014","unstructured":"Barbot M, Albiger N, Ceccato F et al (2014) Combination therapy for Cushing\u2019s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary 17:109\u2013117","journal-title":"Pituitary"},{"key":"1342_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1530\/EJE-10-0382","volume":"163","author":"A Godbout","year":"2010","unstructured":"Godbout A, Manavela M, Danilowicz K et al (2010) Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease. Eur J Endocrinol 163:709\u2013716","journal-title":"Eur J Endocrinol"},{"key":"1342_CR14","doi-asserted-by":"publisher","first-page":"968","DOI":"10.4158\/EP10031.OR","volume":"16","author":"AR Lila","year":"2010","unstructured":"Lila AR, Gopal RA, Acharya SV et al (2010) Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract 16:968\u2013976","journal-title":"Endocr Pract"},{"key":"1342_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","volume":"13","author":"L Vilar","year":"2010","unstructured":"Vilar L, Naves LA, Azevedo MF et al (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease. Pituitary 13:123\u2013129","journal-title":"Pituitary"},{"key":"1342_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H","volume":"11","author":"S Seedat","year":"2000","unstructured":"Seedat S, Kesler S, Niehaus DJ et al (2000) Pathological gambling behaviour: emergence secondary to treatment of Parkinson\u2019s disease with dopaminergic agents. Depress Anxiety 11:185\u2013186","journal-title":"Depress Anxiety"},{"key":"1342_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.physbeh.2011.04.055","volume":"104","author":"JE Ahlskog","year":"2011","unstructured":"Ahlskog JE (2011) Pathological behaviors provoked by dopamine agonist therapy of Parkinson\u2019s disease. Physiol Behav 104:168\u2013172","journal-title":"Physiol Behav"},{"key":"1342_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","volume":"133","author":"D Weintraub","year":"2017","unstructured":"Weintraub D, Claassen DO (2017) Impulse control and related disorders in Parkinson\u2019s disease. Int Rev Neurobiol 133:679\u2013717","journal-title":"Int Rev Neurobiol"},{"key":"1342_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1055\/s-0037-1601887","volume":"37","author":"AM Lopez","year":"2017","unstructured":"Lopez AM, Weintraub D, Claassen DO (2017) Impulse control disorders and related complications of Parkinson\u2019s disease therapy. Semin Neurol 37:186\u2013192","journal-title":"Semin Neurol"},{"key":"1342_CR20","doi-asserted-by":"publisher","first-page":"R88","DOI":"10.1530\/EC-18-0030","volume":"7","author":"AP Athanasoulia-Kaspar","year":"2018","unstructured":"Athanasoulia-Kaspar AP, Popp KH, Stalla GK (2018) Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist. Endocr Connect 7:R88\u2013R94","journal-title":"Endocr Connect"},{"key":"1342_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1210\/clinem\/dgz076","volume":"105","author":"SMC De Sousa","year":"2020","unstructured":"De Sousa SMC, Baranoff J, Rushworth RL et al (2020) Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab 105:108\u2013118. https:\/\/doi.org\/10.1210\/clinem\/dgz076","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589\u2013595","journal-title":"Arch Neurol"},{"key":"1342_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/WNF.0b013e31820d6699","volume":"34","author":"D Dang","year":"2011","unstructured":"Dang D, Cunnington D, Swieca J (2011) The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol 34:66\u201370","journal-title":"Clin Neuropharmacol"},{"key":"1342_CR24","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen SC, Cikrikcili U, Oruk G et al (2019) Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab 104:2527\u20132534","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1530\/EJE-12-0198","volume":"167","author":"AP Athanasoulia","year":"2012","unstructured":"Athanasoulia AP, Sievers C, Ising M et al (2012) Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol 167:327\u2013335","journal-title":"Eur J Endocrinol"},{"key":"1342_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11154-009-9123-7","volume":"11","author":"N Sonino","year":"2010","unstructured":"Sonino N, Fallo F, Fava GA (2010) Psychosomatic aspects of Cushing\u2019s syndrome. Rev Endocr Metab Disord 11:95\u2013104","journal-title":"Rev Endocr Metab Disord"},{"key":"1342_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A et al (2015) The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med 12:e1001885","journal-title":"PLoS Med"},{"key":"1342_CR28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","volume":"56","author":"AT Beck","year":"1988","unstructured":"Beck AT, Epstein N, Brown G et al (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893","journal-title":"J Consult Clin Psychol"},{"key":"1342_CR29","first-page":"118","volume":"6","author":"N Hisli","year":"1988","unstructured":"Hisli N (1988) Beck Depresyon Envanterinin gecerliligi uzerine bit calisma (A study on the validity of Beck Depression Inventory). Psikoloji Dergisi 6:118\u2013122","journal-title":"Psikoloji Dergisi"},{"key":"1342_CR30","unstructured":"Envanteri UMBA (1993) Ge\u00e7erlik ve g\u00fcvenirlik \u00e7al\u0131\u015fmas\u0131. Yay\u0131nlanmam\u0131\u015f uzmanl\u0131k tezi Bak\u0131rk\u00f6y Ruh ve Sinir Hastal\u0131klar\u0131 Hastanesi, \u0130stanbul"},{"key":"1342_CR31","unstructured":"Derogatis LR (1992) SCL-90-R: administration, scoring & procedures manual-II for the (revised) version and other instruments of the psychopathology rating scale series. Clin Psychom Res 1\u201316"},{"key":"1342_CR32","unstructured":"Da\u011f I (1991) Belirti Tarama Listesi (Scl-90-R)\u2019nin \u00dcniversite \u00d6\u011frencileri i\u00e7in g\u00fcvenirli\u011fi ve ge\u00e7erli\u011fi. T\u00fcrk Psikiyatri Dergisi [Reliability and validity of the Symptom Check List (SCL-90-R) for university students]. T\u00fcrk Psikiyatri Dergisi 2(1):5\u201312"},{"key":"1342_CR33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1","volume":"51","author":"JH Patton","year":"1995","unstructured":"Patton JH, Stanford MS, Barratt ES (1995) Factor structure of the barratt impulsiveness scale. J Clin Psychol 51:768\u2013774","journal-title":"J Clin Psychol"},{"key":"1342_CR34","first-page":"251","volume":"18","author":"H G\u00fcle\u00e7","year":"2008","unstructured":"G\u00fcle\u00e7 H, Tamam L, G\u00fcle\u00e7 MY et al (2008) Psychometric properties of the Turkish version of the Barratt Impulsiveness Scale-11. Klinik Psikofarmakoloji B\u00fclteni 18:251\u2013258","journal-title":"Klinik Psikofarmakoloji B\u00fclteni"},{"key":"1342_CR35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.psychres.2018.05.006","volume":"265","author":"SR Chamberlain","year":"2018","unstructured":"Chamberlain SR, Grant JE (2018) Minnesota Impulse Disorders Interview (MIDI): validation of a structured diagnostic clinical interview for impulse control disorders in an enriched community sample. Psychiatry Res 265:279\u2013283","journal-title":"Psychiatry Res"},{"key":"1342_CR36","first-page":"5","volume":"55","author":"GA Christenson","year":"1994","unstructured":"Christenson GA, Faber RJ, De Zwaan M et al (1994) Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 55:5\u201311","journal-title":"J Clin Psychiatry"},{"key":"1342_CR37","volume-title":"Impulse control disorders: a clinicians guide to understanding and treating behavioral addictions","author":"JE Grant","year":"2008","unstructured":"Grant JE (2008) Impulse control disorders: a clinicians guide to understanding and treating behavioral addictions. WW Norton & Company, New York"},{"key":"1342_CR38","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/mds.22571","volume":"24","author":"D Weintraub","year":"2009","unstructured":"Weintraub D, Hoops S, Shea JA et al (2009) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease. Mov Disord 24:1461\u20131467","journal-title":"Mov Disord"},{"key":"1342_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0010-0277(94)90018-3","volume":"50","author":"A Bechara","year":"1994","unstructured":"Bechara A, Damasio AR, Damasio H et al (1994) Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50:7\u201315","journal-title":"Cognition"},{"key":"1342_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF00401506","volume":"11","author":"MH Orzack","year":"1967","unstructured":"Orzack MH, Kornetsky C, Freeman H (1967) The effects of daily administration of carphenazine on attention in the schizophrenic patient. Psychopharmacologia 11:31\u201338","journal-title":"Psychopharmacologia"},{"key":"1342_CR41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0920-9964(00)00060-8","volume":"48","author":"MM Kurtz","year":"2001","unstructured":"Kurtz MM, Ragland JD, Bilker W et al (2001) Comparison of the continuous performance test with and without working memory demands in healthy controls and patients with schizophrenia. Schizophr Res 48:307\u2013316","journal-title":"Schizophr Res"},{"key":"1342_CR42","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington, DC"},{"key":"1342_CR43","first-page":"242","volume":"55","author":"SL McElroy","year":"1994","unstructured":"McElroy SL, Keck PE Jr, Pope HG Jr et al (1994) Compulsive buying: a report of 20 cases. J Clin Psychiatry 55:242\u2013248","journal-title":"J Clin Psychiatry"},{"key":"1342_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/mds.20045","volume":"19","author":"AH Evans","year":"2004","unstructured":"Evans AH, Katzenschlager R, Paviour D et al (2004) Punding in Parkinson\u2019s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19:397\u2013405","journal-title":"Mov Disord"},{"key":"1342_CR45","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1210\/jc.2012-3200","volume":"98","author":"X Bertagna","year":"2013","unstructured":"Bertagna X, Guignat L (2013) Approach to the Cushing\u2019s disease patient with persistent\/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab 98:1307\u20131318","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR46","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","volume":"103","author":"S Bhasin","year":"2018","unstructured":"Bhasin S, Brito JP, Cunningham GR et al (2018) Testosterone therapy in men with hypogonadism: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab 103:1715\u20131744","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR47","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1210\/jc.2017-00131","volume":"102","author":"CM Gordon","year":"2017","unstructured":"Gordon CM, Ackerman KE, Berga SL et al (2017) Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 102:1413\u20131439","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR48","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1210\/jc.2015-2236","volume":"100","author":"CA Stuenkel","year":"2015","unstructured":"Stuenkel CA, Davis SR, Gompel A et al (2015) Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 100:3975\u20134011","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR49","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BMK, Findling JW et al (2008) The diagnosis of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 93:1526\u20131540","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR50","doi-asserted-by":"publisher","first-page":"967","DOI":"10.4103\/0028-3886.237019","volume":"66","author":"S Bhattacharjee","year":"2018","unstructured":"Bhattacharjee S (2018) Impulse control disorders in Parkinson\u2019s disease: review of pathophysiology, epidemiology, clinical features, management, and future challenges. Neurol India 66:967\u2013975","journal-title":"Neurol India"},{"key":"1342_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11154-022-09709-w","volume":"23","author":"A Hamidianjahromi","year":"2022","unstructured":"Hamidianjahromi A, Tritos N (2022) Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Rev Endocr Metab Disord 23:1\u201311","journal-title":"Rev Endocr Metab Disord"},{"key":"1342_CR52","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/mds.25291","volume":"28","author":"J Bastiaens","year":"2013","unstructured":"Bastiaens J, Dorfman BJ, Christos PJ et al (2013) Prospective cohort study of impulse control disorders in Parkinson\u2019s disease. Mov Disord 28:327\u2013333","journal-title":"Mov Disord"},{"key":"1342_CR53","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","volume":"17","author":"M Barake","year":"2014","unstructured":"Barake M, Evins AE, Stoeckel L et al (2014) Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary 17:150\u2013156","journal-title":"Pituitary"},{"key":"1342_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","volume":"41","author":"M Grall-Bronnec","year":"2018","unstructured":"Grall-Bronnec M, Victorri-Vigneau C, Donnio Y et al (2018) Dopamine agonists and impulse control disorders: a complex association. Drug Saf 41:19\u201375","journal-title":"Drug Saf"},{"key":"1342_CR55","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1176\/appi.ajp.2008.08081201","volume":"166","author":"DA Pizzagalli","year":"2009","unstructured":"Pizzagalli DA, Holmes AJ, Dillon DG et al (2009) Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry 166:702\u2013710","journal-title":"Am J Psychiatry"},{"key":"1342_CR56","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.yhbeh.2016.05.005","volume":"84","author":"VL Kinner","year":"2016","unstructured":"Kinner VL, Wolf OT, Merz CJ (2016) Cortisol alters reward processing in the human brain. Horm Behav 84:75\u201383","journal-title":"Horm Behav"},{"key":"1342_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1176\/ajp.156.2.181","volume":"156","author":"JJ Mann","year":"1999","unstructured":"Mann JJ, Waternaux C, Haas GL et al (1999) Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 156:181\u2013189","journal-title":"Am J Psychiatry"},{"key":"1342_CR58","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fpsyt.2018.00465","volume":"9","author":"J Mar\u00edn-Lahoz","year":"2018","unstructured":"Mar\u00edn-Lahoz J, Pagonabarraga J, Martinez-Horta S et al (2018) Parkinson\u2019s disease: impulsivity does not cause impulse control disorders but boosts their severity. Front Psychiatry 9:465","journal-title":"Front Psychiatry"},{"key":"1342_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/EJE-18-0682","volume":"180","author":"AG Ioachimescu","year":"2019","unstructured":"Ioachimescu AG, Fleseriu M, Hoffman AR et al (2019) Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol 180:31\u201340","journal-title":"Eur J Endocrinol"},{"key":"1342_CR60","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00023210-200115050-00003","volume":"15","author":"N Sonino","year":"2001","unstructured":"Sonino N, Fava GA (2001) Psychiatric disorders associated with Cushing\u2019s syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 15:361\u2013373","journal-title":"CNS Drugs"},{"key":"1342_CR61","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1176\/ajp.144.7.951","volume":"144","author":"JI Hudson","year":"1987","unstructured":"Hudson JI, Hudson MS, Griffing GT et al (1987) Phenomenology and family history of affective disorder in Cushing\u2019s disease. Am J Psychiatry 144:951\u2013953","journal-title":"Am J Psychiatry"},{"key":"1342_CR62","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000012396","volume":"69","author":"N Sonino","year":"2000","unstructured":"Sonino N, Boscaro M, Fallo F et al (2000) A clinical index for rating severity in Cushing\u2019s syndrome. Psychother Psychosom 69:216\u2013220","journal-title":"Psychother Psychosom"},{"key":"1342_CR63","first-page":"2647","volume":"81","author":"N Sonino","year":"1996","unstructured":"Sonino N, Zielezny M, Fava GA et al (1996) Risk factors and long-term outcome in pituitary-dependent Cushing\u2019s disease. J Clin Endocrinol Metab 81:2647\u20132652","journal-title":"J Clin Endocrinol Metab"},{"key":"1342_CR64","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price J, Bertagna X, Grossman AB et al (2006) Cushing\u2019s syndrome. Lancet 367:1605\u20131617","journal-title":"Lancet"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01342-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01342-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01342-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T08:15:07Z","timestamp":1690964107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01342-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1342"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01342-3","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"12 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study was approved by the Medical Research Ethics Committee of Cerrahpasa Medical School (02.06.2021-103521). All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}